Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
05/18/17Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present preclinical data on SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with hypomethylating agents and anti-CD38 therapies in genomically ... 
Printer Friendly Version
05/15/17Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
– Dosed First Patient in Phase 1 Clinical Trial of SY-1365 in Patients with Advanced Solid Tumors – – Expanded Phase 2 Clinical Trial of SY-1425 to Include Combination Dosing Arm; On Track to Report Initial Clinical Data in Fall 2017 – – Closed Private Placement for $35 Million in Gross Proceeds – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the d... 
Printer Friendly Version
05/15/17Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced today that the first patient has been dosed in the Phase 1 clinical trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors, including transcriptionally... 
Printer Friendly Version
05/08/17Syros Announces Late-Breaking Oral Presentation on its Research Identifying Key Genes that Control the Auto-immune Response in Lupus at FOCIS Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company’s research identifying key genes that control T cell activation in systemic lupus erythematosus (SLE) will be highlighted in a late-breaking oral presentation at the 17th Annual Meeting of the Fede... 
Printer Friendly Version
05/08/17Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2017-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced new preclinical data that further elucidates the mechanism of action of SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist currently in a Phase 2 clinical trial in genomically defined ... 
Printer Friendly Version
05/04/17Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer
– Analysis of Regulatory Genome Leads to 14 New Drug Targets – – Data Presented at IMPAKT Breast Cancer Conference – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced new data generated using its gene control platform, including the discovery of 14 new drug ... 
Printer Friendly Version
05/01/17Syros Participates in International Symposium to Support MDS Foundation’s Efforts to Raise Awareness of Novel Therapies in Development for MDS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present on SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist currently in a Phase 2 clinical trial in genomically defined subsets of patients with acute myeloid l... 
Printer Friendly Version
04/27/17Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined Subsets of Patients at IMPAKT Breast Cancer Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 27, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present data demonstrating the power of its drug discovery and development platform to identify novel drug targets and associated biomarkers linked to genomically defined subsets of breast cancer ... 
Printer Friendly Version
04/26/17Syros Closes $35 Million Private Financing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced today that it has closed a previously announced private financing with a select group of existing and new institutional investors. At the closing, the Company issued 2,592,591 shares of common stock at a price of $13.50 per sh... 
Printer Friendly Version
04/21/17Syros Announces $35 Million Private Placement
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 21, 2017-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced today that it has entered into a stock purchase agreement with several institutional accredited investors for the private placement of 2,592,591 shares of common stock at a purchase price of $13.50 per share, yielding expected... 
Printer Friendly Version
04/18/17Syros to Present on SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present new preclinical data on SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist currently in a Phase 2 clinical trial in genomically defined subsets of patien... 
Printer Friendly Version
04/10/17Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
– Company on Track to Initiate Study in Second Quarter of 2017 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 10, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's Investigational New Drug (IND) application to advance SY-1365, its first-in-cl... 
Printer Friendly Version
04/04/17Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RARα Agonist, for Genomically Defined AML and MDS Patients
– New Preclinical Data Demonstrate Synergistic Anti-Tumor Activity of SY-1425 with Standard-of-Care AML and MDS Therapies, Providing Evidence for Expansion of Ongoing Phase 2 Clinical Trial to Include Combination with Azacitidine – – New Preclinical Data Show SY-1425 Sensitizes AML Cells with High RARA Expression to Approved Multiple Myeloma Drug by Inducing Expression of CD38, Providing Rationale for Clinical Investigation of SY-1425 in C... 
Printer Friendly Version
04/03/17Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors
– New Data Demonstrate SY-1365 Inhibits Tumor Growth in In Vivo Models of Triple Negative Breast Cancer – – New Data Show SY-1365 Has Anti-Proliferative Activity in Additional Cancer Cells, including Ovarian and Small Cell Lung Cancers – – New Data on CDK12 and CDK13 Inhibitor Program Highlight Company’s Leadership in Transcriptional CDKs – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 3, 2017-- Syros Pharmaceuticals (NASDAQ:SYRS), a... 
Printer Friendly Version
03/20/17Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
– Presented Data at Key Medical Meetings Further Supporting Therapeutic Potential of SY-1425 in Genomically Defined AML, MDS and Breast Cancer Patients – – Highlighted Data at Scientific Conferences Demonstrating Productivity of Syros’ Gene Control Platform in Oncology and Immuno-oncology – – On Track to Report Initial Clinical Data on SY-1425 in Fall 2017 – – On Track to Initiate Phase 1 Clinical Trial of SY-1365 in ... 
Printer Friendly Version
03/01/17Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at Upcoming AACR Annual Meeting
Presentations Highlight Therapeutic Potential of Company’s Clinical and Preclinical Programs and Leadership in Gene Control CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that the Company will present new data on three of its clinical and preclinical programs at the Am... 
Printer Friendly Version
03/01/17Syros Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that members of its management team will present at upcoming investor conferences. Details are as follows: Cowen and Company 37th Annual Health Care Conference Date: Wednesday, March 8 Presentation Time: 11:20 ... 
Printer Friendly Version
02/27/17Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference
Analysis of the Regulatory Genome Provides New Approach for AML Patient Stratification Independent of Genomic Mutations Super-enhancers Shown to be Associated with Survival Outcomes and Response to Therapies in Development CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving ... 
Printer Friendly Version
02/21/17Syros’ Drug Discovery Research in Immuno-Oncology Highlighted at UCSD Moores Cancer Center Symposium
Company Identifies Alterations in the Regulatory Genome of Tumor-Associated Macrophages in Subset of Pancreatic Cancer Patient Tissues Findings Underscore the Promise of the Syros’ Gene Control Platform to Yield Important Insights into Thwarting Cancer’s Ability to Evade the Immune System CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 21, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the developmen... 
Printer Friendly Version
02/09/17Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2017-- Syros Pharmaceuticals (NASDAQ:SYRS) today announced the publication of a paper in a special cancer-focused issue of the scientific journal Cell that highlights gene control as an important area for cancer drug discovery and development, underscoring the promise of Syros’ pioneering approach to advance a new wave of medicines that control the expression of disease-driving genes. The paper, w... 
Printer Friendly Version
02/07/17Syros Pharmaceuticals to Present at 2017 BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the 2017 BIO CEO & Investor Conference. Details are as follows: 2017 BIO CEO & Investor Conference Date: Tuesday, Feb... 
Printer Friendly Version
01/30/17Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced the appointment of Peter Wirth as Chair of the Company’s Board of Directors. Mr. Wirth is an industry veteran with a track record of value creation in biotechnology. "Peter is a recognized leader in the biotech industry whose... 
Printer Friendly Version
01/10/17Syros to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at the 35th Annual J.P. Morgan Healthcare Conference. Details are as follows: 35th Annual J.P. Morgan Healthcare Conference Date: ... 
Printer Friendly Version
01/09/17Syros Pharmaceuticals Announces 2017 Strategic Priorities and Goals
2016 Accomplishments Put Company on Track to Achieve Significant 2017 Clinical Milestones Initial Data Readout from Ongoing Phase 2 Clinical Trial of SY-1425, Its First-in-Class Selective RARα Agonist, in Subsets of AML and MDS Patients Expected in Fall of 2017 SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Expected to Advance into Phase 1 Clinical Trial in First Half of 2017 Company Also Reveals New Preclinical Prog... 
Printer Friendly Version